
Subject: original dutagen?

Posted by [demo99](#) on Tue, 03 Oct 2006 13:44:19 GMT

[View Forum Message](#) <> [Reply to Message](#)

hallo,

möchte einen dutagenvergleich machen. sind diese hier original?
Ich glaube schon.

Bitte stellt auch eure fotos rein,

danke im voraus

mfg demo99

File Attachments

1) [blister_a.jpg](#), downloaded 415 times

Dutasteride Soft

DUTAGEN

TM WARN
Dutas
wome
not ha
of the
poter
Manu
Dr. RE
Shop
Somn
at: 19
Marke

Each soft gelatin capsule contains:
Dutasteride 0.5 mg

COLOURS: Iron Oxide Black
& Iron Oxide Red

DOSAGE: As directed by the Physician.
Store below 25°C. Protect
from light & moisture.

WARNING: To be sold by retail on the

2) [blister_a.jpg](#), downloaded 354 times

Dutasteride Soft

DUTAGEN

TM WARN
Dutas
wome
not ha
of the
poten
Manu
Dr. RE
Shop
Somn
at: 19
Marke

Each soft gelatin capsule contains:
Dutasteride 0.5 mg

COLOURS: Iron Oxide Black
& Iron Oxide Red

DOSAGE: As directed by the Physician.
Store below 25°C. Protect
from light & moisture.

WARNING: To be sold by retail on the

3) [package insert.jpg](#), downloaded 341 times

For the use only of a straight or a bent

DUTAGE

(Dutasteride Soft Gelatin)


COMPOSITION

Each soft gelatin capsule contains

Dutasteride 0.5 mg

DESCRIPTION

Dutasteride is a synthetic 5- α -reductase inhibitor that is a selective inhibitor of both type 1 and type 2 5- α -reductase enzymes that convert testosterone to dihydrotestosterone (DHT). It is designated as (11 β ,13 β ,14 β ,17 β)-17 α -acetyl-3-oxo-5 α -androstane-2,14-dione, representing a molecular weight of 386.5.



Dutasteride
Dutasteride (Dutasteride)

Pharmacokinetics

Effectiveness of Dutasteride

Dutasteride inhibits the conversion of testosterone to the 5 α -reduced androgen, DHT, by the initial development and subsequent emergence of the prostate gland. Two types of 5 α -reductase, which exist as 2 isoforms, type 1 and type 2. The type 2 isoform is responsible for the conversion of testosterone to DHT in the skin and the type 1 isoform is also responsible for testosterone conversion in the skin. Dutasteride is a competitive and specific inhibitor of both type 1 and type 2 5 α -reductase enzymes. Pharmacokinetic data for dutasteride has been established using 14C-labeled dutasteride in a phase I study.

The maximum effect of daily doses of dutasteride on the reduction of DHT in the skin was observed 1 and 2 weeks of daily therapy with dutasteride 0.5 mg. Similar results were observed in patients with DHT treated with dutasteride 0.5 mg/day for 1 and 2 years and 10% of 2 years. The maximum increase in total testosterone was 10% of the baseline range.

In 10% patients treated with 0.5 mg/day of dutasteride or placebo for up to 12 weeks, mean DHT concentrations in prostatic tissue were significantly lower in the 0.5 mg group, respectively, 2 and 10%. Mean prostatic tissue concentrations of dutasteride group compared with placebo (0.5 mg and 10 mg), respectively, 2 and 10 mg, were significantly affected type 2 5 α -reductase activity. The effect was sufficient to reduce type 2 5 α -reductase activity throughout the study. The mean increase in total testosterone was 10% of the baseline range. There was no effect on the 5 α -reductase activity in the skin. There was no effect on the 5 α -reductase activity in the skin. There was no effect on the 5 α -reductase activity in the skin. There was no effect on the 5 α -reductase activity in the skin.